Compare Agilent Technologies Inc (A) vs Boeing Co (BA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs Boeing Co — how do they compare? Agilent Technologies Inc trades at $128.39 (market cap $37.04B), while Boeing Co trades at $223.55 (market cap $182.63B). The key difference: Boeing Co is far larger — about 4.9× Agilent Technologies Inc's market cap, and Agilent Technologies Inc pays the higher dividend (0.78%). Which is the better fit depends on your goals.
| A | BA | |
|---|---|---|
Market Cap | $37.04B | $182.63B |
Sector | Health | Industrials |
52-Week High | $157.20 | $252.15 |
52-Week Low | $110.24 | $179.12 |
Enterprise Value | $38.59B | $208.94B |
Dividend Yield | 0.78% | 0.03% |
Volume | — | 7,591,579 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
Boeing (BA) trades at $231.68, up 2.29% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $268.33. The company returned to profitability in 2025 with $2.24B net income on $89.46B revenue, though valuation ratios like P/E of 92.7 remain elevated. Recent news highlights defense contract wins and production expansion, including a new 737 assembly line.
Outlook: Boeing's recovery trajectory offers upside potential driven by operational improvements and strong backlog, but high debt, thin margins, and execution risks pose challenges. Analyst sentiment is predominantly bullish, yet investors should weigh valuation concerns against growth catalysts in the aerospace cycle.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Boeing Co
The Boeing Company, together with its subsidiaries, develops, produces, and markets commercial jet aircraft, as well as provides related support services to the commercial airline industry worldwide. The Company also researches, develops, produces, modifies, and supports information, space, and defense systems, including military aircraft, helicopters and space and missile systems.
Read more on BA →
